Aurinia Pharmaceuticals Inc (AUP):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Aurinia Pharmaceuticals Inc (AUP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8272
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:49
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:カナダ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Aurinia Pharmaceuticals Inc (Aurinia Pharmaceuticals), formerly Isotechnika Pharma Inc, is a clinical stage biopharmaceutical company which develops and commercializes therapies for the treatment of debilitating diseases. Voclosporin, the company’s product candidate under clinical development, is an investigational drug for the treatment of lupus nephritis and focal segmental glomerulosclerosis; and voclosporin ophthalmic solution for dry eye syndrome. It serves the needs of patients and physicians by providing access to therapeutic options and disease awareness. Aurinia Pharmaceuticals works in partnership with patient advocacy groups, healthcare providers and researchers to deliver treatments to people suffering from debilitating diseases. It has operations in Canada and the US. Aurinia Pharmaceuticals is headquartered in Victoria, British Columbia, Canada.

Aurinia Pharmaceuticals Inc (AUP) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Aurinia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Aurinia Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Aurinia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Aurinia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Aurinia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Aurinia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Merger 11
Isotechnika Pharma And Aurinia Pharma Complete Merger 11
Equity Offering 13
Aurinia Pharma Files Shelf Prospectus to Raise up to USD250 Million in Public Offering of Securities 13
Aurinia Pharma Raises USD173.1 Million in Public Offering of Shares 14
Aurinia Pharma Raises USD28.8 Million in Public Offering of Units 16
Aurinia Pharma Raises USD7 Million in Private Placement of Shares 18
Aurinia Pharma Completes Private Placement Of Units For US$52 Million 19
Asset Transactions 21
Ciclofilin Pharma Acquires NICAMs Assets from Aurinia Pharma 21
Aurinia Pharmaceuticals Inc – Key Competitors 22
Aurinia Pharmaceuticals Inc – Key Employees 23
Aurinia Pharmaceuticals Inc – Locations And Subsidiaries 24
Head Office 24
Other Locations & Subsidiaries 24
Recent Developments 25
Financial Announcements 25
Aug 09, 2018: Aurinia reports second quarter financial results and operational highlights 25
May 10, 2018: Aurinia Announces 2018 First Quarter Financial Results 27
Mar 15, 2018: Aurinia Reports Fourth Quarter and Full Year 2017 Financial Results and Operational Highlights 29
Nov 14, 2017: Aurinia Reports Third Quarter 2017 Financial Results and Provides Operational Highlights 31
Aug 10, 2017: Aurinia Reports Second Quarter 2017 Financial Results, and Provides Operational Highlights 32
May 15, 2017: Aurinia Reports First Quarter 2017 Financial Results 33
Mar 09, 2017: Aurinia Reports Fourth Quarter and Full Year 2016 Financial Results and Recent Operational Highlights 35
Corporate Communications 37
Feb 22, 2018: Aurinia Enhances Research, Development, and Scientific Expertise with the Appointment of Michael Hayden to its Board of Directors 37
Feb 08, 2018: Aurinia Enhances Commercial and Business Development Expertise with the Appointment of Joseph P. Hagan to its Board of Directors 38
Dec 11, 2017: Aurinia Pharmaceuticals Added to the NASDAQ Biotech Index 39
Feb 06, 2017: Aurinia Pharmaceuticals appoints chairman and CEO 40
Product News 41
03/27/2017: Aurinia Highlights 48-Week Data from Open-Label AURION Study at 12th International Congress on SLE (LUPUS 2017) & the 7th Asian Congress on Autoimmunity (ACA 2017) 41
03/06/2017: Aurinia Announces Acceptance of Voclosporin Late-Breaking Presentation at the National Kidney Foundation 2017 Spring Clinical Meetings 42
02/06/2017: Aurinia Announces Appointment of Company Founder, Dr. Richard M. Glickman, as its New Chief Executive Officer 43
Clinical Trials 44
Oct 20, 2017: Aurinia Launches Development Program for Treatment of Dry Eye Syndrome 44
Mar 01, 2017: Aurinia Announces Voclosporin Meets 48-Week Remission Endpoints, Achieving Highest Complete Remission Rate of Any Global Lupus Nephritis Study 45
Feb 14, 2017: Aurinia Announces Results from Japanese Phase I Ethnic Bridging Study for Voclosporin 46
Jan 27, 2017: Aurinia Selects Worldwide Clinical Trials as its CRO for Phase 3 Lupus Nephritis Trial 47
Other Significant Developments 48
Feb 14, 2018: Aurinia Pharmaceuticals Launches New Lupus Nephritis Disease Awareness Program 48
Appendix 49
Methodology 49
About GlobalData 49
Contact Us 49
Disclaimer 49

List of Tables
Aurinia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Aurinia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Aurinia Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Aurinia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Aurinia Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Aurinia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Isotechnika Pharma And Aurinia Pharma Complete Merger 11
Aurinia Pharma Files Shelf Prospectus to Raise up to USD250 Million in Public Offering of Securities 13
Aurinia Pharma Raises USD173.1 Million in Public Offering of Shares 14
Aurinia Pharma Raises USD28.8 Million in Public Offering of Units 16
Aurinia Pharma Raises USD7 Million in Private Placement of Shares 18
Aurinia Pharma Completes Private Placement Of Units For US$52 Million 19
Ciclofilin Pharma Acquires NICAMs Assets from Aurinia Pharma 21
Aurinia Pharmaceuticals Inc, Key Competitors 22
Aurinia Pharmaceuticals Inc, Key Employees 23
Aurinia Pharmaceuticals Inc, Other Locations 24
Aurinia Pharmaceuticals Inc, Subsidiaries 24

List of Figures
Aurinia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Aurinia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Aurinia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Aurinia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Aurinia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Aurinia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Aurinia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Aurinia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Aurinia Pharmaceuticals Inc (AUP):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • TELUS Corporation:企業の戦略・SWOT・財務分析
    TELUS Corporation - Strategy, SWOT and Corporate Finance Report Summary TELUS Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Bioasis Technologies Inc (BTI):製薬・医療:M&Aディール及び事業提携情報
    Summary Bioasis Technologies Inc (BTI) is a developer and commercialize of pharmaceutical products and diagnostic technologies for central nervous system diseases and disorders. The company’s transcend program describes the proprietary carrier, p97 to deliver therapeutics and imaging agents across t …
  • Vyome Biosciences Pvt Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Vyome Biosciences Pvt Ltd (Vyome) is a clinical-stage biopharmaceutical company that develops novel drugs for antibiotic-resistant acne, other skin pathogens and anti-fungal agents in dermatology. The company’s pipeline products include VB 1953, VB 6345, VB 9333 and VB 9450. Its products are …
  • Sandoz Inc-製薬・医療分野:企業M&A・提携分析
    Summary Sandoz Inc (Sandoz), a division of Novartis AG, is a generic pharmaceutical company that develops, manufactures and distributes and sells a range of prescription medicines and protein and biotechnology-based products known as biosimilars. The company also provides intermediary products inclu …
  • Cisco Systems, Inc (CSCO)-石油・ガス分野:企業M&A・提携分析
    Summary Cisco Systems, Inc (Cisco) is a technology services provider, which designs, manufactures and sells Internet protocol (IP)-based networking systems and other products. The company’s products include blade switches, analytics and automation software, application networking services, interface …
  • OncoResponse Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary OncoResponse Inc (OncoResponse) focuses on the discovery, development and commercialization of therapeutic antibodies for the treatment of cancer. The company’s lead program includes ONCR-201, an anti-EMP2 fully-human monoclonal antibody, which is developed for female malignancies. It utiliz …
  • Beckman Coulter Inc:企業の戦略的SWOT分析
    Beckman Coulter Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Time Dotcom Berhad (TIMECOM):企業の財務・戦略的SWOT分析
    Time Dotcom Berhad (TIMECOM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • SQZ Biotechnologies Co:製薬・医療:M&Aディール及び事業提携情報
    Summary SQZ Biotechnologies Co (SQZ) develops cell-based therapies that harness the body’s natural immune system against cancer. The company utilizes CellSqueeze, a technology platform for engineering various cell functions as antigen presenting cells (APCs) for immune modulation to impact oncology …
  • EZCORP Inc (EZPW):企業の財務・戦略的SWOT分析
    EZCORP Inc (EZPW) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Wahl Clipper Corporation:企業の戦略・SWOT・財務情報
    Wahl Clipper Corporation - Strategy, SWOT and Corporate Finance Report Summary Wahl Clipper Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Yue Yuen Industrial (Holdings) Limited (551):企業の財務・戦略的SWOT分析
    Yue Yuen Industrial (Holdings) Limited (551) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key stren …
  • Nasdaq, Inc. (NDAQ):企業の財務・戦略的SWOT分析
    Nasdaq, Inc. (NDAQ) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Emerson Electric Co (EMR):企業の財務・戦略的SWOT分析
    Emerson Electric Co (EMR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Coutts & Co:企業の戦略・SWOT・財務分析
    Coutts & Co - Strategy, SWOT and Corporate Finance Report Summary Coutts & Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • TeneoBio Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary TeneoBio Inc (TeneoBio), formerly OMT Therapeutics Inc is a biotechnology company. The company develops biologics, human heavy chain antibodies as therapeutics that targets the cancer, autoimmunity, and infectious diseases. Its pre-clinical pipeline portfolio includes antibodies such as mult …
  • Immatics Biotechnologies GmbH:企業の戦略的SWOT分析
    Immatics Biotechnologies GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • Oasmia Pharmaceutical AB (OASM):企業の財務・戦略的SWOT分析
    Summary Oasmia Pharmaceutical AB (Oasmia Pharmaceutical) is a pharmaceutical company that develops, manufactures, markets and sells drugs for human and veterinary oncology. The company’s pipeline for human health includes apealea (paclical), currently at registration and approval stage, for treating …
  • RELX Group plc:企業の戦略・SWOT・財務情報
    RELX Group plc - Strategy, SWOT and Corporate Finance Report Summary RELX Group plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • JA Solar Holdings Co Ltd (JASO):電力:M&Aディール及び事業提携情報
    Summary JA Solar Holdings Co Ltd (JA Solar) is a developer and provider of solar photovoltaic products. The company designs, develops, manufactures and sells silicon wafers, solar cells and solar modules. It offers both monocrystalline and mulicrystalline solar cells and modules. JA Solar also provi …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆